At the news
? NEUTRALIMPACT 2/10 PRESS-RELEASE filed Aug 21, 2026 at 17:15 ET
Iovance Biotherapeutics granted inducement stock options covering 240,135 shares to 20 new non-executive employees at an exercise price of $8.99 per share. This is a routine equity grant to attract and retain new hires, with no material financial impact or change to the company's outlook.
- Grant of 240,135 inducement stock options to 20 new non-executive employees
- Exercise price of $8.99 per share, equal to the closing price on August 20, 2026
- Options vest over three years: one-third on first anniversary, remainder quarterly over next two years
- Granted under Iovance's Amended and Restated 2021 Inducement Plan per Nasdaq Listing Rule 5635(c)(4)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access